ClinicalTrials.gg
CompletedNCT00623805Updated Aug 8, 2014Results posted

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of Bevacizumab and Capecitabine in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 10 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
66th of 224
123 · median 63
Started
2008
with 9 others
Phase 3
42 of 230
4 open now
Registered
61st of 230
by date
Lead sponsor
22 of 230
Hoffmann-La Roche

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 66th largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2008, is one of 42 in phase 3, and was the 61st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal cancer. Patients were randomized into one of 2 groups to receive 1) Xeloda + oxaliplatin + Avastin until disease progression or 2) Xeloda + oxaliplatin + Avastin for 6 3-week cycles, followed by Xeloda + Avastin until disease progression. Xeloda was administered at a dose of 1000 mg/m\^2 orally twice a day on days 1-14 of each cycle, oxaliplatin at a dose of 130 mg/m\^2 intravenously (iv) on day 1 of each cycle, and Avastin at a dose of 7.5 mg/kg iv on day 1 of each cycle.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age.
  • confirmed colon or rectal cancer, with unresectable disease.
  • At least 1 .
  • Outpatient, with (ECOG) Performance Status = 0-1.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Avastin.
  • Previous systemic treatment for advanced or disease.
  • cardiovascular disease.
  • Daily chronic treatment with high doses of aspirin (> 325 mg/day) or non-steroidal anti-inflammatory drugs.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    Bevacizumab+capecitabine+oxaliplatin

    Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.

    Drug: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin

  • Experimental
    Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C

    Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.

    Drug: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • Bevacizumab was supplied as a solution in single-use vials.

    Also known as: Avastin

  • Capecitabine was supplied as film-coated tablets.

    Also known as: Xeloda

  • Oxaliplatin was supplied as a lyophilized powder in vials.

    Also known as: Eloxatin

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from the first administration of study drug to the first documented disease progression or death, whichever occurs first. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the first administration of study drug to death.

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

  2. Percentage of Participants With a Complete Response or a Partial Response

    A complete response was defined as the disappearance of all target lesions. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the Baseline sum longest diameter. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. All other lesions (or sites of disease) should be identified as non-target lesions. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

  3. Time Until a Complete Response or a Partial Response

    Time until a complete response or a partial response was defined as the time from the first administration of study drug until the first complete response or partial response.

    Time frame: Baseline to Month 13

  4. Duration of Response

    Duration of response was defined as the time from the first complete response or partial response until disease progression or death. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

  5. Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

  6. Percentage of Participants With a R0 Resection

    An R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.

    Time frame: Baseline to the end of the study (up to 4 years, 2 months)

07

Results

Posted Aug 8, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Started6261
Completed4239
Not completed2022
Withdrew: Adverse event96
Withdrew: Death20
Withdrew: Lack of efficacy37
Withdrew: Lost to follow-up22
Withdrew: Protocol violation11
Withdrew: Reason not specified36

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from the first administration of study drug to the first documented disease progression or death, whichever occurs first. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

Time frame:
Baseline to the end of the study (up to 4 years, 2 months)
Reported as:
Mean · Months
Progression-free Survival
MonthsBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Progression-free Survival9.0 ± 0.712.6 ± 1.0
SecondaryOverall Survival

Overall survival was defined as the time from the first administration of study drug to death.

Time frame:
Baseline to the end of the study (up to 4 years, 2 months)
Reported as:
Mean · Months
Overall Survival
MonthsBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Overall Survival21.0 ± 1.325.4 ± 1.7
SecondaryPercentage of Participants With a Complete Response or a Partial Response

A complete response was defined as the disappearance of all target lesions. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the Baseline sum longest diameter. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. All other lesions (or sites of disease) should be identified as non-target lesions. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

Time frame:
Baseline to the end of the study (up to 4 years, 2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Complete Response or a Partial Response
Percentage of participantsBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Percentage of Participants With a Complete Response or a Partial Response53.259.0
SecondaryTime Until a Complete Response or a Partial Response

Time until a complete response or a partial response was defined as the time from the first administration of study drug until the first complete response or partial response.

Time frame:
Baseline to Month 13
Reported as:
Mean · Months
Time Until a Complete Response or a Partial Response
MonthsBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Time Until a Complete Response or a Partial Response3.5 ± 2.82.9 ± 2.0
SecondaryDuration of Response

Duration of response was defined as the time from the first complete response or partial response until disease progression or death. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.

Time frame:
Baseline to the end of the study (up to 4 years, 2 months)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery
Time frame:
Baseline to the end of the study (up to 4 years, 2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery
Percentage of participantsBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery58.154.1
SecondaryPercentage of Participants With a R0 Resection

An R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.

Time frame:
Baseline to the end of the study (up to 4 years, 2 months)

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab+Capecitabine+Oxaliplatin—12/62 (19.4%)62/62 (100%)
Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C—21/61 (34.4%)61/61 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
Clinical worseningGeneral disorders0/622/61
DiarrheaGastrointestinal disorders2/622/61
Urinary tract infectionInfections and infestations1/622/61
Abdominal painGastrointestinal disorders1/621/61
Angina pectorisCardiac disorders0/621/61
AnorexiaGastrointestinal disorders0/621/61
BronchospasmRespiratory, thoracic and mediastinal disorders0/621/61
Decreased breath sounds on right lower zoneRespiratory, thoracic and mediastinal disorders0/621/61
Defence, distension and rigidity in abdomenGastrointestinal disorders0/621/61
Difficulty in breathingRespiratory, thoracic and mediastinal disorders0/621/61
Most frequent other events
Most frequent other events
EventBevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C
NauseaGastrointestinal disorders27/6217/61
NeuropathyNervous system disorders25/6225/61
Hemifacial spasmVascular disorders23/6224/61
VomitingGastrointestinal disorders24/6216/61
WeaknessGeneral disorders24/6218/61
DiarrheaGastrointestinal disorders24/6217/61
AnorexiaGastrointestinal disorders17/6213/61

Baseline characteristics

Intent-to-treat population: All randomized participants with a least 1 post-randomization efficacy assessment.

Age, Continuous
Age, Continuous(years)Bevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+CTotal
Mean56.9 ± 11.257.6 ± 11.357.2 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab+Capecitabine+OxaliplatinBevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+CTotal
Female232346
Male393877
08

Study locations

10 sites
  • Ankara, 06100, Turkey
  • Ankara, 06500, Turkey
  • Ankara, 06590, Turkey
  • Gaziantep, 27310, Turkey
  • Istanbul, 34300, Turkey
  • Istanbul, 34390, Turkey
  • Istanbul, 34890, Turkey
  • Izmir, 35100, Turkey
  • Izmir, 35340, Turkey
  • S?hhiye, ANKARA, 06100, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2008
First posted
Feb 26, 2008
Start
Mar 2008
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Aug 8, 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00623805
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2008
Start date
Mar 2008
Primary completion
May 2012
Completion
May 2012
Results posted
Aug 8, 2014
Last update
Aug 8, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine · Oxaliplatin

Start the discussion